Published in J Pediatr on January 01, 1988
Clinical pharmacokinetics in infants and children. A reappraisal. Clin Pharmacokinet (1989) 1.30
Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med (1985) 8.16
Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA (1999) 7.37
Production of collagenase and prostaglandins by isolated adherent rheumatoid synovial cells. Proc Natl Acad Sci U S A (1976) 5.40
Stimulation of rheumatoid synovial cell collagenase and prostaglandin production by partially purified lymphocyte-activating factor (interleukin 1). Proc Natl Acad Sci U S A (1981) 4.89
Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med (1988) 4.69
Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum (1990) 4.39
CCR5 is characteristic of Th1 lymphocytes. Nature (1998) 3.92
Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum (1995) 3.83
Use of calcium excretion values to distinguish two forms of primary renal tubular hypokalemic alkalosis: Bartter and Gitelman syndromes. J Pediatr (1992) 3.78
Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells. J Clin Invest (1986) 3.43
Participation of monocyte-macrophages and lymphocytes in the production of a factor that stimulates collagenase and prostaglandin release by rheumatoid synovial cells. J Clin Invest (1979) 3.34
Collagenase production by rheumatoid synovial cells: stimulation by a human lymphocyte factor. Science (1977) 2.91
Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages. J Exp Med (1984) 2.78
Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis (2000) 2.59
Prostaglandin production by rheumatoid synovial cells: stimulation by a factor from human mononuclear Cells. J Exp Med (1977) 2.47
Longitudinal analyses of renal lesions due to acute pyelonephritis in children and their impact on renal growth. J Urol (2008) 2.31
Purification of a factor from human blood monocyte-macrophages which stimulates the production of collagenase and prostaglandin E2 by cells cultured from rheumatoid synovial tissues. FEBS Lett (1981) 2.27
A urine inhibitor of interleukin 1 activity that blocks ligand binding. J Immunol (1987) 2.17
Cortical scintigraphy in the evaluation of renal parenchymal changes in children with pyelonephritis. J Pediatr (1994) 2.15
Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine (2000) 2.11
Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. J Biol Chem (1989) 2.07
High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. Am Rev Respir Dis (1992) 2.05
Relation between tumor necrosis factor-alpha and granulocyte elastase-alpha 1-proteinase inhibitor complexes in the plasma of patients with cystic fibrosis. Am Rev Respir Dis (1989) 1.99
Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol (1998) 1.97
Purification and characterization of human interleukin-1 beta expressed in recombinant Escherichia coli. Eur J Biochem (1986) 1.89
A human inhibitor of tumor necrosis factor alpha. J Exp Med (1988) 1.85
Are younger children at highest risk of renal sequelae after pyelonephritis? Lancet (1997) 1.84
Increased prostaglandin production by human monocytes after membrane receptor activation. J Immunol (1979) 1.77
Synthesis of interleukin 1/endogenous pyrogen in the brain of endotoxin-treated mice: a step in fever induction? J Immunol (1984) 1.71
Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s). J Clin Invest (1986) 1.70
Interleukin 1 is present in normal human epidermis. J Immunol (1986) 1.70
Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol (1998) 1.70
IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest (1995) 1.69
Primary hypomagnesemia with secondary hypocalcemia in an infant. Pediatrics (1968) 1.66
Induction of human interleukin 1 mRNA measured by collagenase- and prostaglandin E2-stimulating activity in rheumatoid synovial cells. Eur J Immunol (1984) 1.66
Purified blood monocytes from HIV 1-infected patients produce high levels of TNF alpha and IL-1. Clin Immunol Immunopathol (1989) 1.63
IFN-gamma and 1,25(OH)2D3 induce on THP-1 cells distinct patterns of cell surface antigen expression, cytokine production, and responsiveness to contact with activated T cells. J Immunol (1992) 1.62
Crucial role of tumor necrosis factor (TNF) receptor 2 and membrane-bound TNF in experimental cerebral malaria. Eur J Immunol (1997) 1.56
Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production. J Immunol (1990) 1.48
Macrophage inflammatory protein-1: a prostaglandin-independent endogenous pyrogen. Science (1989) 1.46
Cytokines and other mediators in rheumatoid arthritis. Springer Semin Immunopathol (1984) 1.45
A urine inhibitor of interleukin 1 activity affects both interleukin 1 alpha and 1 beta but not tumor necrosis factor alpha. J Immunol (1987) 1.44
Atrial natriuretic factor in patients with congenital heart disease: correlation with hemodynamic variables. J Am Coll Cardiol (1990) 1.41
Suppression of metalloproteinase biosynthesis in human alveolar macrophages by interleukin-4. J Clin Invest (1992) 1.38
Direct contact between T lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression. J Biol Chem (1994) 1.36
Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol (1997) 1.32
Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF receptor. Proc Natl Acad Sci U S A (1990) 1.30
Imbalance between interstitial collagenase and tissue inhibitor of metalloproteinases 1 in synoviocytes and fibroblasts upon direct contact with stimulated T lymphocytes: involvement of membrane-associated cytokines. Arthritis Rheum (1998) 1.30
Recurrent de novo mitochondrial DNA mutations in respiratory chain deficiency. J Med Genet (2003) 1.30
Limited effects of recombinant human and murine interleukin 1 and tumour necrosis factor on production of acute phase proteins by cultured rat hepatocytes. Biochem Int (1987) 1.30
The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis. Arthritis Rheum (2000) 1.29
Matrix metalloproteinases and TIMP in acute respiratory distress syndrome. Am J Respir Crit Care Med (1996) 1.29
Purification and characterization of human interleukin-1 alpha produced in Escherichia coli. Eur J Biochem (1987) 1.28
Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1 beta by monocytic cells: a possible role of CD69. Eur Cytokine Netw (1993) 1.26
Killing of Staphylococcus aureus by tumor necrosis factor-alpha-activated neutrophils. The role of serum opsonins, integrin receptors, respiratory burst, and degranulation. J Immunol (1993) 1.25
Interactions among rheumatoid synovial cells and monocyte-macrophages: production of collagenase-stimulating factor by human monocytes exposed to concanavalin A or immunoglobulin Fc fragments. J Immunol (1980) 1.24
The functional importance of a cap site-proximal region of the human prointerleukin 1 beta gene is defined by viral protein trans-activation. Mol Cell Biol (1992) 1.24
Response to 2-deoxy-D-glucose and to glucagon in "ketotic hypoglycemia" of childhood: evidence for epinephrine deficiency and altered alanine availability. Pediatr Res (1973) 1.24
Interferon-beta not only inhibits interleukin-1beta and tumor necrosis factor-alpha but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. Eur Cytokine Netw (1997) 1.23
Mononuclear cell-conditioned medium containing mononuclear cell factor (MCF), homologous with interleukin 1, stimulates collagen and fibronectin synthesis by adherent rheumatoid synovial cells: effects of prostaglandin E2 and indomethacin. Coll Relat Res (1985) 1.22
Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. Crit Care Med (1996) 1.19
Localization of [3H]ouabain-sensitive Na+ pump sites in cultured pig kidney cells. Am J Physiol (1979) 1.19
Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis. Lancet (1987) 1.19
25-hydroxyvitamin D and calcium levels in maternal, cord and infant serum in relation to maternal vitamin D intake. Helv Paediatr Acta (1978) 1.18
Human Th1 cells preferentially induce interleukin (IL)-1beta while Th2 cells induce IL-1 receptor antagonist production upon cell/cell contact with monocytes. Eur J Immunol (1997) 1.18
Procalcitonin, IL-6, IL-8, IL-1 receptor antagonist and C-reactive protein as identificators of serious bacterial infections in children with fever without localising signs. Eur J Pediatr (2001) 1.18
Randomised controlled trial of three day versus 10 day intravenous antibiotics in acute pyelonephritis: effect on renal scarring. Arch Dis Child (2001) 1.17
Modulation of endotoxic activity of lipopolysaccharide by high-density lipoprotein. Pathobiology (1991) 1.17
Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. The J5 Study Group. Immunology (1992) 1.16
The insulin receptor of a human monocyte-like cell line: characterization and function. Endocrinology (1984) 1.16
Hormonal changes in puberty III: Correlation of plasma dehydroepiandrosterone, testosterone, FSH, and LH with stages of puberty and bone age in normal boys and girls and in patients with Addison's disease or hypogonadism or with premature or late adrenarche. J Clin Endocrinol Metab (1975) 1.15
Production of monoclonal antibodies against interleukin-1 alpha and -1 beta. Development of two enzyme immunometric assays (EIA) using acetylcholinesterase and their application to biological media. J Immunol Methods (1989) 1.15
The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J Clin Invest (1995) 1.15
Rheumatoid synovial cell morphologic changes induced by a mononuclear cell factor in culture. Arthritis Rheum (1983) 1.14
A cell strain cultured from porcine kidney increases cyclic AMP content upon exposure to calcitonin or vasopressin. Biochem Biophys Res Commun (1978) 1.14
Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study. Rheumatology (Oxford) (2001) 1.14
Induction of plasma inhibitors of interleukin 1 and TNF-alpha activity by endotoxin administration to normal humans. Am J Physiol (1990) 1.14
Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. J Rheumatol (1997) 1.13
Inhibition by retinoic acid of collagenase production in rheumatoid synovial cells. N Engl J Med (1980) 1.12
Successful treatment of polyarteritis nodosa related to hepatitis B virus with a combination of lamivudine and interferon alpha. Rheumatology (Oxford) (1999) 1.12
Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response. Arthritis Rheum (1994) 1.12
Pyridoxine-dependent seizures, clinical and therapeutic aspects. Eur J Pediatr (1991) 1.11
Purification and characterization of a 26-kDa competitive inhibitor of interleukin 1. Eur J Immunol (1990) 1.10
Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. Clin Exp Rheumatol (1993) 1.09
IFN-beta inhibits the ability of T lymphocytes to induce TNF-alpha and IL-1beta production in monocytes upon direct cell-cell contact. Cytokine (2001) 1.09
Radioimmunoassay of melatonin: human serum and cerebrospinal fluid. Horm Res (1977) 1.09
Normal epidermis contains high amounts of natural tissue IL 1 biochemical analysis by HPLC identifies a MW approximately 17 Kd form with a P1 5.7 and a MW approximately 30 Kd form. Lymphokine Res (1986) 1.09
Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum (1993) 1.08
Tumor necrosis factor and interleukin-1 activities in free lung cells after single and repeated inhalation of bacterial endotoxin. Infect Immun (1991) 1.07
Characterization of cells from human giant cell tumors of bone. Clin Orthop Relat Res (1986) 1.07
Contact-dependent stimulation of monocytic cells and neutrophils by stimulated human T-cell clones. Immunology (1995) 1.07
Serum cytokine changes in systemic vasculitis. Immunology (1989) 1.05